Pathogenetic concepts of acute coronary syndromes
Roberto Corti, MD*,
Valentin Fuster, MD, PhD, FACC*,* and
Juan Jose Badimon, PhD, FACC*
* Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai School of Medicine, New York, New York, USA
Manuscript received May 7, 2002;
accepted August 4, 2002.
*
Reprint requests and correspondence: Dr. Valentin Fuster, Mount Sinai School of Medicine, Box 1030, New York, New York 10029 USA.
valentin.fuster{at}mssm.edu
The propensity of plaque to disrupt is a major determinant of future ischemic events. Although they are distinct from one another, the atherosclerotic and thrombotic processes appear to be interdependent and may be integrated under the term "atherothrombosis." It is now clear that plaque composition, rather than the percent stenosis, is a major determinant of plaque vulnerability. Plaque disruption seems to depend on both passive and active phenomena and is not purely mechanical. Inflammation (activation of monocytes/macrophages) is a major determinant of both plaque vulnerability and thrombogenicity as they relate to plaque disruption. In one-third of acute coronary syndromes, there is, however, no plaque disruption but only superficial erosion of a markedly stenotic, fibrotic plaque. In these cases, thrombus formation may be exacerbated by a hyperthrombogenic state present in patients with certain systemic risk factors. The endothelium plays a pivotal role in vascular homeostasis and hemostasis. This dynamic organ regulates blood thrombogenicity as well as contractile, secretory, and mitogenic activities in the vessel wall. Some classic risk factors induce endothelial dysfunction by reducing the bioavailability of nitric oxide, increasing tissue endothelin-1, and activating pro-inflammatory signaling pathways. Vascular hemostasis, which is the maintenance of blood fluidity and vascular integrity, is achieved by counter-balancing the intrinsic clotting tendency of blood. As a consequence of the central role of endothelial cells in hemostatic control, a dysfunctional endothelium will generate a pro-thrombotic environment favoring development of atherosclerotic lesions and thrombotic complications.
|
Abbreviations and Acronyms
| | ACS | = acute coronary syndrome(s) | | CRP | = C-reactive protein | | ET | = endothelin | | ICAM | = intercellular adhesion molecule | | LDL | = low-density lipoprotein | | MMP | = matrix metalloproteinase | | NO | = nitric oxide | | PGI | = prostaglandin inhibitor | | SMC | = smooth muscle cell(s) | | TF | = tissue factor | | TFPI | = tissue factor pathway inhibitor | | TIMP | = tissue inhibitor of metalloproteinases | | VCAM | = vascular cell adhesion molecule |
|
This article has been cited by other articles:
|
|
|
|
 
D. Shimbo, W. Chaplin, S. Kuruvilla, L. T. Wasson, D. Abraham, and M. M. Burg
Hostility and Platelet Reactivity in Individuals Without a History of Cardiovascular Disease Events
Psychosom Med,
September 1, 2009;
71(7):
741 - 747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rajappa, S.K. Sen, and A. Sharma
Role of Pro-/Anti-Inflammatory Cytokines and Their Correlation With Established Risk Factors in South Indians With Coronary Artery Disease
Angiology,
August 1, 2009;
60(4):
419 - 426.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T Kilic, D Ural, E Ural, Z Yumuk, A Agacdiken, T Sahin, G Kahraman, G Kozdag, A Vural, and B Komsuoglu
Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome
Heart,
August 1, 2006;
92(8):
1041 - 1046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Antoniades, D. Tousoulis, C. Vasiliadou, E. Stefanadi, K. Marinou, and C. Stefanadis
Genetic Polymorphisms of Platelet Glycoprotein Ia and the Risk for Premature Myocardial Infarction: Effects on the Release of sCD40L During the Acute Phase of Premature Myocardial Infarction
J. Am. Coll. Cardiol.,
May 16, 2006;
47(10):
1959 - 1966.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Stone and H. D. Aronow
Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy
Mayo Clin. Proc.,
May 1, 2006;
81(5):
641 - 652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. C. Chen and O. Ogut
Decline of contractility during ischemia-reperfusion injury: actin glutathionylation and its effect on allosteric interaction with tropomyosin
Am J Physiol Cell Physiol,
March 1, 2006;
290(3):
C719 - C727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Antoniades, D. Tousoulis, C. Vasiliadou, C. Pitsavos, C. Chrysochoou, D. Panagiotakos, C. Tentolouris, K. Marinou, N. Koumallos, and C. Stefanadis
Genetic Polymorphism on Endothelial Nitric Oxide Synthase Affects Endothelial Activation and Inflammatory Response During the Acute Phase of Myocardial Infarction
J. Am. Coll. Cardiol.,
September 20, 2005;
46(6):
1101 - 1109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Priebe
Perioperative myocardial infarction--aetiology and prevention
Br. J. Anaesth.,
July 1, 2005;
95(1):
3 - 19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Nonne, N. Lenain, B. Hechler, P. Mangin, J.-P. Cazenave, C. Gachet, and F. Lanza
Importance of Platelet Phospholipase C{gamma}2 Signaling in Arterial Thrombosis as a Function of Lesion Severity
Arterioscler Thromb Vasc Biol,
June 1, 2005;
25(6):
1293 - 1298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Spuentrup, A. Buecker, M. Katoh, A. J. Wiethoff, E. C. Parsons Jr, R. M. Botnar, R. M. Weisskoff, P. B. Graham, W. J. Manning, and R. W. Gunther
Molecular Magnetic Resonance Imaging of Coronary Thrombosis and Pulmonary Emboli With a Novel Fibrin-Targeted Contrast Agent
Circulation,
March 22, 2005;
111(11):
1377 - 1382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Ambrose and D. J. D'Agate
Plaque rupture and intracoronary thrombus in nonculprit vessels: An eyewitness account
J. Am. Coll. Cardiol.,
March 1, 2005;
45(5):
659 - 660.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-R. Jin, M.-R. Cho, C.-K. Ryu, J.-H. Chung, D.-Y. Yuk, J.-T. Hong, K.-S. Lee, J.-J. Lee, M.-Y. Lee, Y. Lim, et al.
Antiplatelet Activity of J78 (2-Chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an Antithrombotic Agent, Is Mediated by Thromboxane (TX) A2 Receptor Blockade with TXA2 Synthase Inhibition and Suppression of Cytosolic Ca2+ Mobilization
J. Pharmacol. Exp. Ther.,
January 1, 2005;
312(1):
214 - 219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F Viles-Gonzalez, V. Fuster, and J. J Badimon
Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences
Eur. Heart J.,
July 2, 2004;
25(14):
1197 - 1207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Uriarte, R. E. Molestina, R. D. Miller, J. Bernabo, A. Farinati, K. Eiguchi, J. A. Ramirez, and J. T. Summersgill
Effects of Fluoroquinolones on the Migration of Human Phagocytes through Chlamydia pneumoniae-Infected and Tumor Necrosis Factor Alpha-Stimulated Endothelial Cells
Antimicrob. Agents Chemother.,
July 1, 2004;
48(7):
2538 - 2543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Priebe
Triggers of perioperative myocardial ischaemia and infarction
Br. J. Anaesth.,
July 1, 2004;
93(1):
9 - 20.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Keeley and C. L. Grines
Primary Coronary Intervention for Acute Myocardial Infarction
JAMA,
February 11, 2004;
291(6):
736 - 739.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Lutgens, R.-J. van Suylen, B. C. Faber, M. J. Gijbels, P. M. Eurlings, A.-P. Bijnens, K. B. Cleutjens, S. Heeneman, and M. J.A.P. Daemen
Atherosclerotic Plaque Rupture: Local or Systemic Process?
Arterioscler Thromb Vasc Biol,
December 1, 2003;
23(12):
2123 - 2130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
